Unlike in the primary tumor situation, KRAS mutations were not only highly frequent in CMS3 metastases (58.33%) but to an even higher extent detectable in CMS1‐classified samples (66.67%) pointing towards potential metastasis‐specific alterations of KRAS mutation frequencies for CMS1. The gene discussed is KRAS; the disease is neoplasm.